HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy.

AbstractOBJECTIVES:
This study investigated the relationship between hepatitis C virus (HCV) dynamics and sustained virological response (SVR), as well as the efficacy of an extended treatment with telaprevir-based triple therapy among patients with chronic hepatitis C genotype 1b.
METHODS:
Among 220 patients receiving triple therapy for 24 weeks, the SVR rate was analyzed at each time point at which HCV RNA became undetectable. The SVR rates in the patients who did not achieve a rapid virological response (RVR) were compared with those in 27 patients who received triple therapy for 48 weeks.
RESULTS:
The SVR rates of interleukin 28B (IL28B) TT and non-TT patients were 100 versus 66.7% after 1 week, 97.6 versus 72.2% after 2 weeks, 95.2 versus 84.2% after 3 weeks, 93.1 versus 72.2% after 4 weeks, 76.9% versus 11.1% after 6 weeks, and 88.9 versus 14.3% after 8 weeks, respectively. All of the IL28B TT patients who showed undetectable HCV RNA levels until week 8 achieved an SVR. In contrast, the SVR rates in the IL28B non-TT patients who did not achieve RVR with 24 and 48 weeks of treatment were 11.8 and 62.5%, respectively (P=0.017).
CONCLUSION:
These results suggest that an SVR can frequently be achieved by IL28B TT patients, even with 24 weeks of treatment, when HCV RNA remains undetectable until week 8, and also that IL28B non-TT patients should have RVR values to achieve an SVR with 24 weeks of treatment. The SVR rate was low in IL28B non-TT patients treated for 24 weeks who did not achieve an RVR; however, it could increase when the treatment duration was extended to 48 weeks.
AuthorsAi Nakagawa, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hiroshi Abe, Chisa Kondo, Norio Itokawa, Taeang Arai, Satomi Hashimoto, Yoko Matsushita, Takeshi Fukuda, Katsuhisa Nakatsuka, Katsuhiko Iwakiri, Chiaki Kawamoto, Yoshio Aizawa, Choitsu Sakamoto
JournalEuropean journal of gastroenterology & hepatology (Eur J Gastroenterol Hepatol) Vol. 26 Issue 12 Pg. 1329-34 (Dec 2014) ISSN: 1473-5687 [Electronic] England
PMID25357216 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Antiviral Agents
  • Biomarkers
  • IL28B protein, human
  • Interferon-alpha
  • Interleukins
  • Oligopeptides
  • RNA, Viral
  • Recombinant Proteins
  • peginterferon alfa-2b
  • Polyethylene Glycols
  • Ribavirin
  • telaprevir
Topics
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents (therapeutic use)
  • Biomarkers (blood)
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Hepacivirus (drug effects, genetics)
  • Hepatitis C, Chronic (diagnosis, drug therapy, genetics, virology)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Interleukins (genetics)
  • Japan
  • Male
  • Middle Aged
  • Oligopeptides (therapeutic use)
  • Polyethylene Glycols (therapeutic use)
  • RNA, Viral (blood)
  • Recombinant Proteins (therapeutic use)
  • Ribavirin (therapeutic use)
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: